Top 5 pharmaceutical M&A deals this year

The biggest deal so far has actually been Gileads acquisition of Forty Seven for $4.9 billion, substantially lower than the average largest deal, according to EvaluatePharma..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.

While the number of pharmaceutical acquisitions is only a little down in the very first half of 2020, the combined value of merger and acquisition deals has decreased considerably, according to EvaluatePharmas “Pharma, Biotech & & Medtech Half-Year Review 2020.”.

The 5 largest pharmaceuticals M&A deals this year:.

There were 22 pharmaceutical acquisitions in the 2nd quarter of 2020, somewhat listed below the average of 27.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.

Maia Anderson –
Thursday, August 20th, 2020
Print|Email.

Gileads acquisition of Forty Seven– $4.9 billion.
Novo Nordisks acquisition of Corvidia– $2.1 billion.
Alexions acquisition of Portola– $1.4 billion.
Eli Lillys acquisition of Dermira– $1.1 billion.
Takedas divestiture of choose drugs to Hypera Pharma– $825 million.

More short articles on pharmacy: US sues Teva for supposed MS drug kickback schemeJ&& J to acquire Momenta Pharma for $6.5 BWhite House consultant states Kodak execs made dumbest decisions on government loan.